Condition: Diabetes Mellitus, Type 1 · Sponsor: Tandem Diabetes Care, Inc.
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.
This description comes directly from the study's public registry record.
Arthur Senigout · +33 6 85 98 40 44 · record-iq@sanoia.com
Always discuss trial participation with your own doctor first.
| CH Agen-Nérac | Agen, France | Recruiting |
| CHU d'Angers | Angers, France | Recruiting |
| CHU Lyon HFME | Bron, France | Recruiting |
| Centre du Diabète - Diab-e-Care Hospices Civils de Lyon (HCL) | Lyon, France | Recruiting |
| Hôpital Européen (APHM) | Marseille, France | Recruiting |
| GHEF Meaux | Meaux, France | Recruiting |
| CHR Metz-Thionville | Metz, France | Recruiting |
| CHU de Montpellier | Montpellier, France | Recruiting |
| Clinique Saint Jean de Védas | Montpellier, France | Recruiting |
| CHU Nîmes | Nîmes, France | Recruiting |
| Institut St-Pierre | Palavas-les-Flots, France | Recruiting |
| Hôpital Lariboisière | Paris, France | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07211126